The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-11. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
== Products == In terms of molecular structure, one distinguishes first between low-molecular-weight (LMW) and high-molecular-weight (HMW) products. The generally accepted threshold between LMW and HMW is a molecular weight of about 700 g/mol. LMW fine chemicals, also designated as small molecules, are produced by traditional chemical synthesis, by microorganisms (through fermentation or biotransformation), or by extraction from plants and animals. In the production of modern life science products, total synthesis from petrochemicals prevails. HMW products, or large molecules, are obtained mainly through biotechnology processes. Within LMWs, the N-heterocyclic compounds are the most important category; within HMWs, it is peptides and proteins.
Abdominal fullness related to an enlarged spleen (splenomegaly). Enlargement of both the liver and spleen Splenomegaly due to extramedullary hematopoiesis (hematopoiesis occurring outside of the bone marrow) Bone pain Bruising and easy bleeding due to inadequate numbers of platelets Increased risk of thrombosis Cachexia (loss of appetite, weight loss, and fatigue) Fatigue Fevers Chills Weight loss Gout and high uric acid levels Increased susceptibility to infection, such as pneumonia Pallor and shortness of breath due to anemia Leukoerythroblastic smear (tear-drop RBCs, nucleated RBCs, and immature granulocytes) In rarer cases, a raised red blood cell volume Cutaneous myelofibrosis is a rare skin condition characterized by dermal and subcutaneous nodules.
=== Panic disorder === Sertraline is superior to placebo for the treatment of panic disorder. The response rate was independent of the dose. In addition to decreasing the frequency of panic attacks by about 80% (vs. 45% for placebo) and decreasing general anxiety, sertraline resulted in an improvement in quality of life on most parameters. The patients rated as "improved" on sertraline reported better quality of life than the ones who "improved" on placebo. The authors of the study argued that the improvement achieved with sertraline is different and of a better quality than the improvement achieved with a placebo. Sertraline is equally effective for men and women, and for patients with or without agoraphobia. Previous unsuccessful treatment with benzodiazepines does not diminish its efficacy. However, the response rate was lower for the patients with more severe panic. Starting treatment simultaneously with sertraline and clonazepam, with subsequent gradual discontinuation of clonazepam, may accelerate the response. Double-blind comparative studies found sertraline to have the same effect on panic disorder as paroxetine or imipramine. While imprecise, comparison of the results of trials of sertraline with separate trials of other anti-panic agents (clomipramine, imipramine, clonazepam, alprazolam, and fluvoxamine) indicates approximate equivalence of these medications.
Sources: en.wikipedia.org
Freshly made, raw tempeh remains edible for a few days at room temperature. It is neither acidic nor does it contain significant amounts of alcohol. It, however, shows greater resistance to spoilage processes such as lipid peroxidation than unfermented soybeans due to its antioxidant contents. Cooking methods such as tempe kering, the deep-fried and seasoned bits of tempeh allows Tempeh to last for a month or more and still be good to consume, if cooked correctly and stored properly in an air-tight jar. The deep-frying process removes the moisture, preventing further fermentation and deterioration, thus prolonging its shelf life.
The famous "Tajiri-go" bull was born from the "Atsuta tsuru," which is a descendant of the Shusuke tsuru. According to a survey conducted by the Japan Wagyu Registry Association, the pedigree was traced from a database of 718,969 Japanese black cattle mothers registered in Japan, and it was found that 718,330 or 99.9% of them are descended from the Tajiri-go. On the other hand, there are those who are concerned about the current situation in which only the Tajima cattle line represented by the Tajiri-go is spreading and genetic diversity is being lost from Wagyu, and the movement to revive the Takenotani tsuru has been attracting attention in recent years. In 1859, Japan opened the port of Yokohama in accordance with the demands of Western nations. At the same time, a foreign settlement was established in Yokohama. Foreign residents sought cattle for meat from neighboring villages but were refused, so cattle were imported from the U.S., China, and Korea, which gradually became unable to meet the demand. In 1865, before the Port of Kobe was opened, the Hyogo Port Opening Demand Incident occurred, in which nine warships from Britain, France, the Netherlands, and the United States invaded Hyogo Port demanding its opening. At that time, sailors negotiated with local cattle merchants for cattle, which were initially slaughtered on board, but as demand increased, it became necessary to slaughter them on land. 1866 saw the first slaughter of cattle by foreigners in the pine forests of Cape Wadamisaki.
=== Somatic recombination === In neurons of the human brain, somatic recombination occurs frequently in the gene that encodes APP. Neurons from individuals with sporadic Alzheimer's disease show greater APP gene diversity due to somatic recombination than neurons from healthy individuals.
== Further reading == Laurence J. Alison, Marie Eyre: Killer in the Shadows: The Monstrous Crimes of Robert Napper. Pennant Books 2009, ISBN 978-1-906015-49-7. Kevin Brewer: Psychology and Crime. Heinemann Educational Publishers 2000, ISBN 978-0-435-80653-8. Paul Britton: The Jigsaw Man. Corgi Books 1998, ISBN 978-0-552-14493-3. Colin Evans: A Question of Evidence: The Casebook of Great Forensic Controversies, from Napoleon to O.J. Wiley 2002, ISBN 978-0-471-44014-7. Mike Fielder: The Murder of Rachel Nickell. John Blake 2000, ISBN 978-1-85782-338-7. Alex Handscombe: Letting Go: A true story of murder, loss and survival by Rachel Nickell's son. Harper Element 2017, ISBN 978-0008144296. André Hanscombe: The Last Thursday in July. Century 1996 / Arrow 1997, ISBN 978-0-09-917512-4. David Kessler: Rachel Nickell, House of Solomon Ltd, 2001, ISBN 978-1-904037-03-3. Keith Pedder: The Rachel Files, John Blake 2002, ISBN 978-1-904034-30-8. Keith Pedder: Murder on the Common: The Secret Story of the Murder That Shocked a Nation. John Blake 2003, ISBN 978-1-84454-057-0. Colin Stagg, David Kessler: Who Really Killed Rachel? Greenzone Publishing 1999, ISBN 978-0-9582027-2-5. Colin Stagg, David Kessler: The Lizzie James Conspiracy. House of Solomon 2001, ISBN 978-1-904037-00-2. Colin Stagg, Ted Hynds: Pariah: Colin Stagg. Pennant Publishing 2007, ISBN 978-1-906015-10-7. Brent E. Turvey: Criminal Profiling: An Introduction to Behavioral Evidence Analysis Academic Press 2002, ISBN 978-0-12-705041-6.
== Early life == Farthing was born on 22 April 1953 in Christchurch, New Zealand. His father was an accountant and his mother was a music teacher. He was educated at Christ's College, Christchurch, an independent boys school. As a child he had considered entering the priesthood. He went on to study medicine at the University of Otago in Dunedin.
Sources: en.wikipedia.org
== Examples == The FDA runs a medical marijuana IND program (the Compassionate Investigational New Drug program). It stopped accepting new patients in 1992 after public health authorities concluded there was no scientific value to it, and due to President George H. W. Bush administration's desire to "get tough on crime and drugs." As of 2011, four patients continue to receive cannabis from the government under the program. Sanctioned by Executive Order 13139, the US Department of Defense employed an anthrax vaccine classified as an investigational new drug (IND) in its Anthrax Vaccine Immunization Program (AVIP).
Rudolf Aebersold (better known as Ruedi Aebersold; born 12 September 1954) is a Swiss biologist, regarded as a pioneer in the fields of proteomics and systems biology. He has primarily researched techniques for measuring proteins in complex samples, in many cases via mass spectrometry. Ruedi Aebersold is a professor of Systems biology at the Institute of Molecular Systems Biology (IMSB) in ETH Zurich. He was one of the founders of the Institute for Systems Biology in Seattle, Washington, United States where he previously had a research group. Aebersold is known for the development and application of targeted proteomics techniques in the field of biomedical research, in order to understand the function, interaction and localization of each protein in the cell and its changes in disease states. To this end, Ruedi Abersold has made significant contributions in the development and application of targeted proteomics methods, including selected reaction monitoring and data-independent acquisition. Ruedi Aebersold is also recognized for its contributions in the development of standard formats and open source software for the analysis and storage of mass spectrometry and proteomics data, and he is one of the inventors of the Isotope-Coded Affinity Tag (ICAT) technique for quantitative proteomics, a technique that measures the relative quantities of proteins between two sample by using tags containing stable isotopes of different masses. Aebersold is co-founder and scientific advisor of the companies ProteoMediX and Biognosys.
Great consumption of fresh produce, especially cut fruits and vegetables. Wider distribution. Improved electronic reporting of outbreaks. An aging population more susceptible to foodborne illness. Unlike meat, which can be rid of bacteria through proper cooking, fresh produce is often meant to be consumed raw.
The Meal, Ready-to-Eat (MRE) is a self-contained individual United States military ration used by the United States Armed Forces and Department of Defense. It is intended for use by American service members in combat or field conditions where other food is not available. MREs have also been distributed to civilians alongside humanitarian daily rations during natural disasters and wars. The MRE replaced the canned Meal, Combat, Individual (MCI) in 1981. Its garrison ration and group ration equivalent is the Unitized Group Ration (UGR), its in-combat and mobile equivalent is the Close Combat Assault Ration (CCAR), and its long-range and cold weather equivalents are the Long Range Patrol (LRP) and Meal, Cold Weather (MCW) respectively.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.